D-Malic Acid Market latest Statistics on Market Size, Growth, Production, Sales Volume, Sales Price, Market Share and Import vs Export 

D-Malic Acid Market Summary Highlights

The D-Malic Acid Market is entering a phase of application-led specialization as pharmaceutical intermediates, chiral synthesis pathways, and precision food formulation continue to expand across industrial economies. Unlike commodity acidulants, D-malic acid occupies a narrower but technologically critical segment where stereochemical purity and process efficiency determine procurement decisions. By 2026, manufacturers are increasingly shifting toward bio-based synthesis and catalytic fermentation routes to improve optical purity while reducing waste intensity and downstream purification costs.

Demand momentum remains strongest in pharmaceutical synthesis, particularly in Asia-Pacific and North America, where chiral compounds are becoming central to active pharmaceutical ingredient (API) development. Regulatory pressure on synthetic additives in food systems is also supporting gradual substitution toward naturally derived acidification agents, although price sensitivity continues to limit widespread penetration in low-margin food categories.

At the same time, capacity expansion is not uniform across regions. Europe is witnessing slower volume growth due to elevated production costs and stricter environmental compliance standards affecting specialty chemical manufacturing. Conversely, China and India continue to strengthen their positions in stereoisomer chemical production through integrated fermentation infrastructure and lower manufacturing economics.

Technological competitiveness in the D-Malic Acid Market is increasingly linked to purification yield, biocatalyst efficiency, and pharmaceutical-grade consistency rather than pure production scale. Producers capable of maintaining high optical purity above 99% are securing stronger margins in high-value applications.

Statistical Highlights

• The D-Malic Acid Market is estimated to surpass USD 185 million in 2026, with projected CAGR ranging between 5.8% and 7.1% through 2031.
• Pharmaceutical applications account for approximately 38%–42% of global D-malic acid consumption in 2026.
• Bio-based production methods now represent nearly 46% of total manufacturing capacity, compared with less than 33% in 2021.
• Asia-Pacific contributes close to 48% of total market demand, led by China, India, Japan, and South Korea.
• Pharmaceutical-grade purity variants above 99% optical purity command pricing premiums of 22%–30% over industrial grades.
• Fermentation-based D-malic acid manufacturing reduces process waste generation by nearly 18%–24% compared with conventional petrochemical synthesis routes.
• Food and beverage applications contribute approximately 24% of total demand, primarily in specialty beverages and nutraceutical formulations.
• Europe’s specialty organic acid manufacturing costs increased by nearly 11% year-over-year entering 2026 due to energy and compliance pressures.
• Chiral intermediates utilizing D-malic acid in API synthesis are projected to expand at over 8% annually through 2030.
• Contract manufacturing organizations (CMOs) now account for nearly one-third of pharmaceutical procurement volumes within the D-Malic Acid Market.
• Research-grade and laboratory applications collectively contribute around 9%–11% of global revenue generation.

Pharmaceutical Chiral Chemistry Is Reshaping Demand Dynamics

One of the strongest structural drivers in the D-Malic Acid Market is the rapid expansion of chiral pharmaceutical synthesis. Modern drug manufacturing increasingly depends on stereochemically precise intermediates because enantiomeric purity directly influences therapeutic performance, toxicity control, and regulatory acceptance.

D-malic acid has become increasingly valuable in asymmetric synthesis pathways involving cardiovascular drugs, antibiotics, peptide chemistry, and advanced biologics. Pharmaceutical producers are prioritizing optically active intermediates that reduce downstream separation requirements and improve reaction selectivity.

By 2026, more than 60% of late-stage pharmaceutical pipelines in developed economies involve chiral synthesis components. This transition is significantly benefiting specialty stereoisomer suppliers. The United States Food and Drug Administration continues to maintain strict scrutiny over enantiomeric composition in drug applications, encouraging pharmaceutical manufacturers to procure higher-purity intermediates from validated suppliers.

In Asia, API manufacturing clusters across India and China are increasing investment in specialty acid intermediates as export-focused pharmaceutical production expands. India’s pharmaceutical exports are projected to exceed USD 38 billion in 2026, creating downstream opportunities for stereochemical raw material suppliers. The expansion of contract development and manufacturing organizations is further strengthening procurement volumes for D-malic acid in high-purity applications.

Unlike bulk organic acids, pharmaceutical-grade D-malic acid requires rigorous purification, contamination control, and batch consistency. This is driving capital investment toward advanced crystallization systems, membrane separation technologies, and fermentation optimization.

Bio-Based Manufacturing Is Becoming a Competitive Requirement

Sustainability is no longer a secondary positioning strategy within the D-Malic Acid Market. Environmental compliance and customer procurement standards are increasingly influencing manufacturing decisions.

Conventional petrochemical synthesis routes face rising scrutiny because of solvent-intensive processing and higher waste generation. As a result, producers are shifting toward bio-fermentation and enzyme-assisted synthesis technologies capable of lowering carbon intensity while improving stereoselectivity.

Fermentation-derived D-malic acid production capacity is projected to grow at nearly 9% annually through 2030. Several manufacturers are investing in microbial engineering to improve substrate conversion efficiency from glucose, molasses, and biomass-derived feedstocks.

The transition is particularly evident in Europe and Japan, where sustainability-linked procurement frameworks are becoming integrated into specialty chemical sourcing decisions. Industrial buyers in pharmaceutical and nutraceutical sectors increasingly request lifecycle emission disclosures and renewable feedstock traceability.

This shift is also altering competitive economics. While fermentation systems involve higher initial infrastructure expenditure, operational efficiency gains are improving long-term profitability. Reduced purification complexity and lower solvent dependency are decreasing waste treatment costs for integrated facilities.

At the same time, not all manufacturers are positioned equally for this transition. Smaller producers dependent on legacy petrochemical routes are facing margin compression as buyers shift toward cleaner production models.

Functional Beverage Expansion Supports Specialty Acid Consumption

The beverage industry is emerging as a stable secondary growth channel for the D-Malic Acid Market, particularly within premium hydration products, low-sugar formulations, and nutraceutical beverages.

D-malic acid offers flavor-enhancing characteristics and acidity modulation properties that support clean-label beverage development. Manufacturers are increasingly using specialty acid blends to improve tartness stability without excessive sugar dependence.

Global functional beverage sales are projected to exceed USD 240 billion in 2026, with Asia-Pacific contributing the fastest consumption growth. Sports drinks, probiotic beverages, electrolyte formulations, and fortified nutritional drinks are incorporating specialty acid systems to maintain shelf stability and sensory consistency.

Consumer preference shifts away from artificial additives are also influencing formulation chemistry. Food manufacturers are under pressure to simplify ingredient declarations while maintaining flavor integrity. As a result, naturally sourced acidulants are receiving greater formulation attention.

However, penetration remains selective rather than universal. Cost sensitivity continues to restrict widespread adoption of high-purity D-malic acid in mainstream beverage categories where citric acid and fumaric acid remain economically dominant. Consequently, growth is concentrated in premium and specialized formulations rather than high-volume carbonated beverage manufacturing.

Asia-Pacific Maintains Structural Manufacturing Dominance

Asia-Pacific continues to dominate global production and consumption patterns in the D-Malic Acid Market due to integrated chemical manufacturing ecosystems, lower operating costs, and expanding pharmaceutical infrastructure.

China remains the leading producer of specialty malic acid derivatives, supported by large-scale fermentation capability and established export networks. Chinese manufacturers continue expanding high-purity organic acid production lines to meet pharmaceutical and nutraceutical demand from North America and Europe.

India is also strengthening its position as a downstream consumer and processor of specialty organic intermediates. Rapid expansion in domestic pharmaceutical manufacturing, combined with government-backed chemical production initiatives, is supporting regional demand growth.

Japan and South Korea remain technologically influential despite lower production volumes. Companies in these markets focus heavily on pharmaceutical-grade purity optimization, process automation, and research-driven specialty applications.

Meanwhile, Europe faces comparatively slower expansion. Elevated energy prices, stringent emissions regulations, and environmental compliance costs are reducing competitiveness for some regional producers. Several European manufacturers are increasingly relying on imported intermediates while concentrating domestic operations on high-margin purification and customization activities.

High-Purity Production Is Becoming the Core Competitive Differentiator

The D-Malic Acid Market is gradually shifting away from volume-based competition toward quality-based differentiation. Optical purity, trace impurity management, and pharmaceutical certification capabilities are becoming more important than simple manufacturing scale.

High-purity D-malic acid variants above 99% optical purity are experiencing stronger demand growth than industrial-grade products. Pharmaceutical and biotechnology customers increasingly require documentation related to impurity profiling, residual solvent levels, and batch reproducibility.

This trend is intensifying investment in analytical instrumentation, precision separation technologies, and automated quality monitoring systems. Manufacturers unable to maintain stringent consistency standards risk exclusion from regulated pharmaceutical supply chains.

Additionally, long-term supply agreements are becoming more common between specialty chemical producers and pharmaceutical companies. Buyers are prioritizing supply reliability and regulatory compliance amid ongoing concerns regarding raw material disruptions and geopolitical trade instability.

The result is a market environment where technological sophistication increasingly determines profitability. Producers capable of combining bio-based synthesis, high optical purity, and scalable pharmaceutical compliance are expected to capture a disproportionate share of future value creation within the D-Malic Acid Market.

Geographical Demand Dynamics in the D-Malic Acid Market

The geographical structure of the D-Malic Acid Market reflects the broader transformation occurring across pharmaceutical chemistry, specialty food additives, and bio-based intermediate manufacturing. Demand concentration is no longer driven solely by industrial output volume; instead, regional competitiveness increasingly depends on pharmaceutical innovation ecosystems, advanced fermentation infrastructure, and specialty chemical export capabilities.

Asia-Pacific continues to dominate both consumption and supply chains, accounting for nearly half of global D-malic acid demand in 2026. China remains the largest regional contributor due to its extensive pharmaceutical intermediate manufacturing base and large-scale fermentation capacity. Chinese exports of specialty organic intermediates have expanded steadily as domestic producers move beyond commodity acids toward higher-margin stereoisomer products.

The country’s National Bureau of Statistics continues to report strong expansion in fine chemical manufacturing output, particularly in pharmaceutical precursor chemicals and bio-based specialty materials. This industrial scaling directly supports higher procurement volumes for chiral compounds such as D-malic acid.

India is emerging as one of the fastest-growing regional markets within the D-Malic Acid Market. Rising pharmaceutical exports, expansion of contract research organizations, and increased domestic API production are accelerating demand for optically active intermediates. India’s Department of Pharmaceuticals has continued promoting local manufacturing under production-linked incentive schemes, strengthening investments in specialty chemical supply chains.

Japanese demand remains highly quality-focused rather than volume-driven. Pharmaceutical companies and nutraceutical manufacturers in Japan prioritize ultra-high-purity grades with stringent impurity controls. Consequently, Japanese buyers often secure long-term procurement contracts with validated suppliers capable of maintaining consistent optical purity above 99%.

South Korea is also strengthening its position due to rapid growth in biotechnology manufacturing and peptide synthesis applications. Advanced biologics production facilities are increasingly dependent on stereochemically precise intermediates, contributing to stable specialty acid demand.

North America Expands Through Pharmaceutical Specialization

North America represents one of the highest-value regional segments in the D-Malic Acid Market despite lower production concentration compared to Asia-Pacific. The United States continues to lead consumption growth because of expanding pharmaceutical R&D, biotechnology investments, and specialty nutraceutical formulation activity.

The pharmaceutical industry in the United States is projected to maintain annual R&D expenditure above USD 320 billion entering 2026. This environment continues to support demand for chiral intermediates utilized in asymmetric synthesis and regulated drug production.

Biotechnology manufacturing expansion is another major driver. Cell therapy, peptide drugs, and complex biologics increasingly require specialized intermediates with precise stereochemical configurations. D-malic acid suppliers capable of meeting pharmaceutical compliance standards are benefiting from premium pricing opportunities in North America.

At the same time, the region remains partially dependent on imports for specialty organic intermediates. Domestic production costs remain comparatively high because of labor expenses, environmental compliance, and energy pricing. As a result, North American buyers frequently source bulk material from Asia while conducting downstream purification and formulation domestically.

Canada contributes comparatively smaller volumes but continues to strengthen demand through clean-label food formulation and nutraceutical manufacturing. Functional beverage producers are increasingly integrating specialty acid systems into premium wellness products targeting low-sugar and natural ingredient positioning.

Europe Faces Cost Pressures but Retains Technical Strength

The European D-Malic Acid Market is characterized by advanced technical standards but slower production expansion. Germany, France, Switzerland, and Italy remain important hubs for pharmaceutical-grade specialty chemicals, particularly in high-purity applications.

However, elevated operating costs continue affecting regional competitiveness. Energy-intensive chemical processing in Europe has experienced sustained cost inflation since recent energy market disruptions. Several specialty chemical manufacturers are optimizing production portfolios by reducing low-margin output and prioritizing premium-grade products.

The European Chemicals Agency continues tightening sustainability and emissions standards for specialty chemical production. These regulations are accelerating the transition toward bio-based synthesis technologies and lower-waste fermentation systems.

Demand remains relatively resilient because Europe maintains a strong pharmaceutical innovation base. Switzerland and Germany continue to host major pharmaceutical companies focused on chiral drug development, supporting stable procurement for optically active intermediates.

Food and beverage applications are also evolving differently in Europe compared with Asia. Premium natural formulations and clean-label ingredient demand are supporting selective adoption of specialty malic acid derivatives in nutraceutical beverages and functional foods. Nevertheless, cost-sensitive mainstream beverage categories still rely heavily on lower-cost acidulants.

D-Malic Acid Market Segmentation Highlights

By Application

• Pharmaceuticals account for nearly 40% of global D-malic acid consumption in 2026.
• Food and beverage applications contribute approximately 24%–26% of total market demand.
• Nutraceutical and dietary supplement formulations are projected to grow above 7% annually through 2030.
• Laboratory and research applications maintain stable niche demand due to expanding chiral chemistry studies.
• Cosmetic and personal care applications remain limited but are gradually expanding in premium formulations.

By Production Method

• Fermentation-based manufacturing represents nearly 46% of global supply capacity.
• Petrochemical synthesis continues to dominate lower-cost industrial-grade production.
• Enzyme-assisted catalytic processes are gaining adoption in pharmaceutical-grade manufacturing.
• Bio-based production facilities are expanding most rapidly in China, Japan, and Western Europe.

By Purity Grade

• Pharmaceutical-grade material above 99% optical purity generates the highest revenue share.
• Food-grade variants remain price-sensitive and highly competitive.
• Research-grade D-malic acid maintains strong margins despite comparatively low volumes.
• Customized purity specifications are becoming increasingly common in biotechnology applications.

By Region

• Asia-Pacific holds nearly 48% share of global demand.
• North America remains the largest premium-value regional market.
• Europe leads in sustainability-focused specialty chemical manufacturing.
• Latin America and Middle East markets remain comparatively small but show gradual nutraceutical demand growth.

D-Malic Acid Production Landscape and Capacity Expansion

Global D-Malic Acid production is becoming increasingly concentrated around integrated fermentation clusters and pharmaceutical intermediate manufacturing zones. By 2026, total D-Malic Acid production capacity is estimated to exceed 82 kilotons annually, with Asia-Pacific contributing more than 55% of global installed capacity.

China remains the dominant center for D-Malic Acid production due to large-scale feedstock availability, mature fermentation infrastructure, and export-oriented specialty chemical manufacturing. Multiple Chinese producers are expanding biocatalytic synthesis systems to improve yield efficiency and reduce purification costs.

India is also witnessing rising D-Malic Acid production investments as pharmaceutical intermediate demand strengthens domestically. Several manufacturers are integrating upstream fermentation with downstream purification operations to improve margin control and export competitiveness.

Meanwhile, European D-Malic Acid production growth remains comparatively restrained because of stricter environmental compliance costs and elevated energy expenses. Producers in Germany and Switzerland are increasingly focusing on smaller-volume, high-purity pharmaceutical-grade output rather than commodity-scale manufacturing.

Automation is becoming a critical production differentiator globally. Advanced crystallization systems, membrane filtration technologies, and AI-assisted process monitoring are improving yield consistency while reducing impurity variability in high-purity D-malic acid manufacturing.

D-Malic Acid Price Trend and Market Pricing Outlook

The D-Malic Acid Price environment in 2026 reflects the broader imbalance between rising pharmaceutical-grade demand and fluctuating raw material economics. Prices remain highly dependent on purity specifications, feedstock source, and production methodology.

Pharmaceutical-grade D-malic acid with optical purity above 99% continues to command substantial premiums over industrial-grade variants. In several regions, premium pharmaceutical material is priced 25%–35% higher due to stricter quality assurance requirements and higher purification costs.

The D-Malic Acid Price Trend during 2025–2026 has shown moderate upward pressure, primarily driven by rising fermentation feedstock costs, energy inflation, and increased investment in sustainable manufacturing infrastructure.

Glucose and biomass-derived substrates remain critical cost determinants for bio-based manufacturers. Agricultural feedstock volatility in Asia has periodically influenced pricing stability, particularly for fermentation-based producers dependent on corn and sugar derivatives.

Regional pricing divergence has also widened. North America and Europe continue experiencing higher average D-Malic Acid Price levels due to regulatory compliance expenses, pharmaceutical certification requirements, and import dependence for bulk intermediates.

Conversely, China maintains comparatively lower export pricing because of scale advantages and integrated production ecosystems. However, environmental inspections and stricter wastewater treatment requirements are gradually increasing operational expenditures among Chinese specialty chemical manufacturers.

The forward D-Malic Acid Price Trend is expected to remain moderately firm through 2030 as pharmaceutical-grade demand expands faster than high-purity supply capacity. Producers investing in efficient bio-based synthesis and vertically integrated purification systems are expected to maintain stronger pricing power across regulated application segments within the D-Malic Acid Market.

Leading Manufacturers in the D-Malic Acid Market

The competitive structure of the D-Malic Acid Market remains moderately consolidated, with a combination of multinational specialty chemical companies, pharmaceutical-grade reagent suppliers, and regional organic acid manufacturers shaping global supply dynamics. Market leadership is increasingly determined by optical purity capability, fermentation efficiency, pharmaceutical compliance, and export network strength rather than pure production scale alone.

Large manufacturers are investing aggressively in bio-based synthesis technologies and high-purity product lines as pharmaceutical and nutraceutical applications expand. Producers supplying pharmaceutical-grade D-malic acid with purity above 99% continue to secure stronger operating margins compared with food-grade and industrial-grade suppliers.

Several Asian manufacturers have strengthened global positioning through integrated fermentation infrastructure and lower production costs, while Japanese and European companies continue to dominate premium high-purity segments requiring advanced analytical validation and GMP-compliant production systems.

Major Manufacturers Operating in the D-Malic Acid Market

Key manufacturers active in the global D-Malic Acid Market include:

• Bartek Ingredients Inc.
• Thirumalai Chemicals Ltd.
• Fuso Chemical Co., Ltd.
• Jungbunzlauer Suisse AG
• Polynt Group
• Musashino Chemical Laboratory Ltd.
• Wacker Chemie AG
• Shandong Jining Rixing Chemical Co., Ltd.
• Hubei Greenhome Fine Chemical Co., Ltd.
• Galactic S.A.
• Lonza Group
• Anhui Anke Biotechnology Group
• Puyang Yongan Chemical Co.
• KANTO CHEMICAL CO., INC.
• Junsei Chemical Co., Ltd.
• Kishida Chemical Co., Ltd.

D-Malic Acid Market Share by Manufacturers

The D-Malic Acid Market share distribution reflects strong regional concentration across Asia-Pacific and North America. By 2026, the top five manufacturers are estimated to control approximately 48%–54% of global revenue generation, particularly within pharmaceutical-grade and specialty food-grade segments.

Bartek Ingredients maintains a strong position in North America due to its diversified malic acid portfolio serving beverage, confectionery, and specialty ingredient industries. The company’s malic acid product range is widely utilized in acidification systems and flavor enhancement formulations for processed foods and functional beverages. Demand from low-sugar beverages and nutraceutical formulations continues supporting its market presence.

Thirumalai Chemicals has emerged as one of the most influential Asian producers. The company operates large-scale malic acid manufacturing infrastructure in India and maintains export-oriented supply capabilities across pharmaceutical, food, and industrial applications. Its EP-grade and pharmaceutical-focused product lines are increasingly targeting regulated healthcare applications and high-purity synthesis requirements.

Fuso Chemical Co., Ltd. retains strong influence in premium specialty segments of the D-Malic Acid Market. The company is particularly recognized for pharmaceutical and reagent-grade organic acids used in precision synthesis applications. Japanese manufacturers continue holding a disproportionately high share in premium-grade categories because of strict process control and analytical validation capabilities.

Jungbunzlauer Suisse AG continues strengthening its position through sustainability-focused organic acid manufacturing. The company’s bio-based acidulant and specialty ingredient portfolio aligns strongly with clean-label food systems and environmentally compliant production standards increasingly demanded in Europe and North America.

Chinese manufacturers, including Shandong Jining Rixing Chemical and Hubei Greenhome Fine Chemical, are rapidly increasing international market penetration through aggressive export pricing and expanding fermentation capacity. These suppliers are particularly influential in mid-range food-grade and industrial-grade malic acid segments, where cost competitiveness remains a primary purchasing factor.

Meanwhile, specialty reagent companies such as KANTO CHEMICAL, Junsei Chemical, and Kishida Chemical maintain niche but high-value positions within laboratory research and pharmaceutical development applications. Their smaller production volumes are offset by premium pricing tied to analytical-grade quality assurance and ultra-high-purity product offerings.

Product Line Expansion and Specialty Positioning

Competition in the D-Malic Acid Market is increasingly shaped by specialized product differentiation. Manufacturers are no longer competing solely on commodity acid supply but instead on application-specific functionality and purity customization.

Thirumalai Chemicals continues expanding its EP-grade malic acid and export-oriented pharmaceutical product lines targeting regulated healthcare applications. The company also supplies malic acid variants for dental care products, throat lozenges, beverage acidification systems, and personal care formulations.

Bartek Ingredients maintains a broad acidulant portfolio supporting beverage stabilization, confectionery tartness enhancement, and low-sugar flavor systems. Its malic acid solutions are increasingly integrated into premium hydration beverages and nutraceutical drink formulations.

Fuso Chemical focuses heavily on pharmaceutical-grade and high-purity applications where stereochemical consistency and impurity management are critical. Japanese manufacturers continue emphasizing laboratory validation and batch reproducibility as strategic differentiators.

Wacker Chemie AG and Galactic S.A. are expanding sustainable specialty chemical portfolios that include environmentally optimized organic acid production systems. These initiatives are gaining traction as pharmaceutical and food manufacturers strengthen sustainability-linked procurement criteria.

Chinese producers are concentrating on fermentation scale optimization and export flexibility. Several suppliers are investing in downstream purification systems to improve competitiveness in higher-margin pharmaceutical and nutraceutical applications rather than remaining confined to commodity-grade supply.

Competitive Trends Reshaping the D-Malic Acid Market

The D-Malic Acid Market is increasingly transitioning toward technology-intensive competition. Expansion of bio-based fermentation capacity, integration of pharmaceutical-grade purification systems, and long-term supply agreements with API manufacturers are becoming the defining competitive factors.

Manufacturers capable of combining sustainable feedstocks with high optical purity production are expected to secure stronger long-term market share gains. Advanced crystallization systems, membrane filtration technologies, and AI-assisted quality monitoring are increasingly used to improve yield consistency and reduce impurity variability.

Another major trend involves vertical integration. Companies are increasingly combining upstream feedstock processing with downstream purification and packaging operations to improve cost stability and reduce external sourcing dependence.

Contract manufacturing partnerships are also becoming more important. Pharmaceutical companies increasingly prefer validated long-term suppliers capable of guaranteeing stereochemical consistency, regulatory documentation, and uninterrupted supply continuity.

Recent Industry Developments

• February 2026 witnessed additional expansion of specialty acid export operations by Indian manufacturers targeting pharmaceutical customers across Europe and Southeast Asia.
• January 2026 saw multiple Chinese specialty chemical producers increase fermentation-based malic acid production capacity to address rising nutraceutical demand in Asia-Pacific.
• In late 2025, several European manufacturers accelerated investments in sustainable organic acid manufacturing technologies focused on lower-emission fermentation systems.
• During October 2025, Japanese producers expanded high-purity organic acid production capabilities for pharmaceutical intermediate applications.
• August 2025 recorded increased capital expenditure among Indian specialty chemical exporters toward pharmaceutical-grade organic intermediate purification infrastructure.
• Mid-2025 also witnessed growing sourcing diversification strategies among European specialty ingredient manufacturers to reduce dependency on single-region imports.
• North American nutraceutical beverage producers increased procurement agreements for specialty acid blends supporting clean-label and low-sugar formulations throughout 2025.
• Asian suppliers introduced upgraded membrane filtration and crystallization systems during 2025 to improve optical purity consistency in D-malic acid manufacturing.